Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study

INTRODUCTION: Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine implicated in airway inflammation in asthma, from binding to its heterodimeric receptor. In the PATHWAY phase 2b study, tezepelumab significantly reduced exacerbation rate...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Asthma Allergy
Main Authors: Corren, Jonathan, Karpefors, Martin, Hellqvist, Åsa, Parnes, Jane R, Colice, Gene
Formato: Artigo
Idioma:Inglês
Publicado: Dove 2021
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7810672/
https://ncbi.nlm.nih.gov/pubmed/33469316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JAA.S286036
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares